Chen Schor
@ChenSchor
Followers
29
Following
1
Media
1
Statuses
13
President and CEO of Adicet Bio. Excited to help deliver best in class gamma-delta T cell therapies for patients fighting cancer.
Joined March 2017
RT @AdicetBio: When we spend our days developing transformative therapies to defeat cancer, it’s important to take a moment to connect with….
0
1
0
RT @AdicetBio: As our pipeline progresses, we expanded into a new state-of-the-art facility! We look forward to calling this home as we liv….
0
2
0
Presence of gamma-delta1 T cells is strongly associated with survival of patients with Non-Small Cell Lung Cancer and several additional solid tumors. Check recent nature cancer publication June 2022.
1
1
2
RT @AdicetBio: We are pleased to be accepted not only for an oral presentation but also discussion in one of the featured Clinical Science….
0
1
0
RT @AdicetBio: On #WorldCancerDay, we stand in unity with the researchers, volunteers and advocates working to reimagine a world without #c….
0
2
0
RT @AdicetBio: Proud to publish preclinical characterization of the 1st clinical stage gamma delta CAR T cell therapy, ADI-001 for B cell l….
0
5
0
RT @AdicetBio: Leading the next breakthroughs in cell therapy, @AdicetBio CSO, @blake_aftab, discusses the promise of innate, adaptive and….
0
3
0
Happy to share our first publication for ADI-002, @Adicet Bio’s investigational #gammadelta #CAR T #celltherapy for solid tumors targeting GPC-3 – Check it out! @JIT @SITCancer.
jitc.bmj.com
Background Glypican-3 (GPC-3) is an oncofetal protein that is highly expressed in various solid tumors, but rarely expressed in healthy adult tissues and represents a rational target of particular...
0
0
0
We are extremely proud of the interim data we announced today in B-cell Non-Hodgkin’s Lymphoma – and we’re just getting started! #celltherapy #gammadelta #biotechnology #cancer #pioneers.
investor.adicetbio.com
Complete and near complete responses observed with ADI-001 starting at lowest dose level in Phase 1 study for the treatment of B-cell Non-Hodgkin’s Lymphoma (ORR=75%, CR=50%) No ADI-001-related ser...
0
0
2